Table 3.
Emax and AUEC of S-COMT inhibition in relation to placebo following the first (day 1) and the last (day 8) doses of an once-daily oral regimen of opicapone (n = 6 per opicapone dose group; n = 7 for placebo)
| Dose | Day | Emax | AUEC0–24 | ||||
|---|---|---|---|---|---|---|---|
| (mg) | (%) | 95% CI | P value | (%.h) | 95% CI | P value | |
| 5 | 1 | 38.1 | −26, 103 | NS | 565 | −87, 1218 | NS |
| 8 | 69.9 | 46, 94 | <0.0001 | 1329 | 865, 1793 | <0.0001 | |
| 10 | 1 | 48.6 | −16, 113 | NS | 811 | 159, 1464 | <0.05 |
| 8 | 82.8 | 59, 107 | <0.0001 | 1601 | 1137, 2065 | <0.0001 | |
| 20 | 1 | 52.7 | −12, 117 | NS | 1119 | 467, 1772 | <0.001 |
| 8 | 89.9 | 66, 114 | <0.0001 | 1768 | 1305, 2232 | <0.0001 | |
| 30 | 1 | 57.7 | −7, 122 | NS | 1329 | 676, 1981 | <0.0001 |
| 8 | 98.0 | 74, 122 | <0.0001 | 1945 | 1483, 2410 | <0.0001 | |
AUEC(0,24 h), area under the effect (S-COMT activity inhibition) vs. time curve over 24 h (i.e. dosing interval); CI, confidence interval; Emax, maximum S-COMT inhibition; NS, not statistically significant.